SCHEMBL3116975

SCHEMBL3116975

COc1ccc(Cc2cc3ccccc3cn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
CYP11B1 P15538 4/20 0.53
CYP11B2 P19099 4/20 0.53
LTA4H P09960 1/20 0.53
PDE10A Q9Y233 4/20 0.52
POLB P06746 1/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP2D6 P10635 1/20 0.44
ATM Q13315 1/20 0.44
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
FYN P06241 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2A6 P11509 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28771177 0.84 PDE10A (0.55) NPC1RAB9ACYP11B1CYP11B2LTA4H
SCHEMBL23715914 0.83 CYP1A2 (0.48) NPC1RAB9ACYP11B1CYP11B2PDE10A
SCHEMBL3121339 0.83 HTR2B (0.50) RAB9ACYP11B1CYP11B2LTA4HPDE10A
SCHEMBL17664092 0.80 HSP90AB1 (0.47) PDE10ASMN1; SMN2ATMLMNAL3MBTL1
SCHEMBL28844860 0.79 KMT2A (0.49) NPC1RAB9AALDH1A1SMN1; SMN2LMNA
SCHEMBL28903971 0.77 NPC1 (0.51) NPC1RAB9ACYP11B1CYP11B2LTA4H
SCHEMBL6982798 0.76 L3MBTL1 (0.41) NPC1CYP11B1CYP11B2PDE10AATM
SCHEMBL27425206 0.76 NPC1 (0.56) NPC1RAB9ALTA4HPDE10APOLB
SCHEMBL509565 0.76 APP (0.50) CYP11B1CYP11B2LTA4HPDE10AALDH1A1
Ammonia Solution, Strong SCHEMBL28903975 0.76 PDE3B (0.49) CYP11B1CYP11B2LTA4HPDE10AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2143714-B1 TETRAHYDROISOQUINOLINE COMPOUND KOWA CO (JP) 2013-06-05 EP disclosed
EP-2143714-B1 TETRAHYDROISOQUINOLINE COMPOUND KOWA CO (JP) 2013-06-05 EP disclosed
US-8273766-B2 Tetrahydroisoquinoline compound KOWA COMPANY, LTD. (JP) 2012-09-25 US disclosed
US-8273766-B2 Tetrahydroisoquinoline compound KOWA COMPANY, LTD. (JP) 2012-09-25 US disclosed
US-8273766-B2 Tetrahydroisoquinoline compound KOWA COMPANY, LTD. (JP) 2012-09-25 US disclosed
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND KOWA COMPANY, LTD. (JP) 2010-05-13 US disclosed
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND KOWA COMPANY, LTD. (JP) 2010-05-13 US disclosed
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND KOWA COMPANY, LTD. (JP) 2010-05-13 US disclosed
EP-2143714-A1 TETRAHYDROISOQUINOLINE COMPOUND Kowa Company, Ltd. (JP) 2010-01-13 EP disclosed
EP-2143714-A1 TETRAHYDROISOQUINOLINE COMPOUND Kowa Company, Ltd. (JP) 2010-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND CCR3, CCR5, CCR1 NPC1 266/4885RAB9A 2065/4885CYP11B1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.